Pharmaceutical Technology

JUNE 10, 2023

Influenza vaccine 2 is under clinical development by Shanghai Institute of Biological Products and currently in Phase I for Pandemic Influenza. According to GlobalData, Phase I drugs for Pandemic Influenza does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Vaccines 40

Vaccines Immunity Immunization Hospitals 40

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunity Immunization Medical Schools 59

STAT

OCTOBER 29, 2024

Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta.

Vaccines 361

Vaccines Immunity Immunization Drug Development 361

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115

Vaccines Immunity Immunization Drug Development 115

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Drug Development 133

Drug Development Immunity Immunization Vaccines 133

pharmaphorum

OCTOBER 30, 2020

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 That is the basis for filing for emergency use authorisation (EUA) of the vaccine in the US, according to criteria set out by the FDA. billion in deposits for the shot.

Vaccines 100

Vaccines Immunity Immunization Drug Development 100

Pharmaceutical Technology

MARCH 24, 2023

Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.

Vaccines 64

Vaccines Health and Personal Care Stores Immunity Immunization 64

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64

PharmaTech

JUNE 9, 2025

Similarly, while some nanoscale delivery systems can exhibit prolonged lifetimes in the bloodstream, others have short circulation times or can be viewed as foreign materials by the immune system and rapidly cleared. These uncertainties and complexity of nanoscale drug delivery systems often lead to regulatory challenges.

Dosage 52

Dosage Drug Development Immunity Immunization 52

Express Pharma

JULY 3, 2023

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?

Biosimilars 95

Biosimilars Drug Development Generic Medicine Immunity 95

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives.

Drug Development 52

Drug Development Immunity Immunization Hospitals 52

Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Data Insights The gold standard of business intelligence. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Insurance Coverage and Processing 52

Insurance Coverage and Processing Hospitals Communication Pharmaceutical Manufacturing 52

pharmaphorum

OCTOBER 12, 2022

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Del Bourgo highlights that genomic treatments work in a similar way to mRNA, which has been used in COVID-19 vaccines.

Drug Development 105

Drug Development Immunity Immunization Vaccines 105

STAT

MAY 22, 2024

During the Covid-19 pandemic, vaccines were the main line of defense. Startlingly effective shots quickly helped immunize a large portion of the population — at least initially, and in high-income countries. Antiviral treatments were not as impactful. Molnupiravir is taken orally, but is less effective than the other options.

Vaccines 322

Vaccines Immunity Immunization Drug Development 322

pharmaphorum

JANUARY 13, 2022

Other companies with active alpha-synuclein programmes include AstraZeneca and Takeda with antibody MEDI 1342 in phase 2 for Parkinson’s, AC Immune and its vaccine candidate ACI-7104, and small-molecular drug developers including Gain Therapeutics, MODAG, and Alterity Therapeutics.

Immunity 98

Immunity Immunization Drug Development Vaccines 98

pharmaphorum

NOVEMBER 2, 2020

With a collective sense of uncertainty, many are pinning their hopes on a vaccine and treatment, and sophisticated technology could help speed up the process of finding an effective medicine. This knowledge is critical in understanding how effective certain drugs might be in treating the virus. One example is Novartis.

Vaccines 132

Vaccines Drug Development Immunity Diabetes 132

PharmaShots

MARCH 14, 2023

The article focuses on challenges faced in drug development, government incentive programs, grants, and various therapies used to diagnose or treat rare diseases. How challenging is the drug development plan Drug development plans for rare diseases can be circuitous, resulting in fewer participation from companies.

Drug Development 40

Drug Development Immunity Immunization Compounding 40

Express Pharma

MAY 10, 2023

However, this philosophy isn’t just relegated to guiding the practices of medical professionals and drug developers. It extends all the way down to the healthcare sector’s expectations for every component, instrument, and process orbiting the development and manufacture of medicine—especially parenteral drugs.

Packaging 97

Packaging Dosage Labelling Immunity 97

pharmaphorum

SEPTEMBER 2, 2021

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Syntem’s recently disclosed proprietary small molecule ‘covalent immune recruiting’ (CIR) technology that can enhance recognition of various pathologies by the host immune system.

Immunity 52

Immunity Immunization Vaccines Drug Development 52

STAT

JUNE 12, 2025

’s handpicked members of a vaccine advisory committee, see Sen. Bill Cassidy quietly explore a “most-favored nation” pricing policy for prescription drugs, and more. installs vaccine critics on CDC panel Health secretary Robert F.   RFK Jr. Kennedy Jr.

Vaccines 158

Vaccines Drug Development Immunity Immunization 158

pharmaphorum

MARCH 10, 2022

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms. The post Welcome to the 2nd Chronic HBV Drug Development Summit appeared first on.

Drug Development 52

Drug Development Immunity Immunization Vaccines 52

European Pharmaceutical Review

FEBRUARY 13, 2025

As drug developers consider oligos potential, they often explore innovations in chemical modifications and delivery systems to ensure these therapies reach their full potential. Regulatory agencies recommend a tiered approach to assessing potential immune responses.

Compounding 52

Compounding Immunity Immunization Drug Development 52

Pharmacy Times

JUNE 19, 2025

SHOW MORE With robust pipelines, cell therapy remains the major driver for drug development. The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

Express Pharma

APRIL 4, 2024

True enough, the use of liposomes and LNPs as carriers for highly specialised drug and biologic payloads, notably mRNA therapies, has experienced remarkable growth—notably, the initial SARS-CoV-2 vaccines authorised for use employed LNPs as delivery mechanisms for mRNA payloads. So, in that sense, both are effective in drug delivery.

Vaccines 98

Vaccines Compounding Immunity Immunization 98

Pharmaceutical Technology

JUNE 18, 2025

Reports Use of Artificial Intelligence in Pharmaceutical Drug Development a. By GlobalData Learn more about Strategic Intelligence FDA’s strategy on trial designs, vaccines and manufacturing Earlier this month, when the Department of Health and Human Sciences Secretary Robert Kennedy Jr.

Vaccines 52

Vaccines Communication Hospitals Drug Development 52

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Immunity 116

Immunity Immunization Vaccines Hospitals 116

pharmaphorum

AUGUST 23, 2022

With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID. Once the scale of the threat was understood, the pharmaceutical industry reacted with a rapidity and agility that allowed vaccines to be developed at a record rate.

Vaccines 134

Vaccines Immunity Immunization Drug Development 134

Pharmaceutical Technology

JUNE 5, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immunity 52

Immunity Immunization Drug Development Vaccines 52

PharmaShots

FEBRUARY 21, 2023

Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. The company is developing PPMX-T002, an anti-cancer drug with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (90Y).

Dosage 56

Dosage Labelling Immunity Immunization 56

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Vaccitech and the Ludwig Institute are providing the drug while the Centre manages the trial and provides funding.

Immunity 64

Immunity Immunization Vaccines Drug Development 64

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion. Moreover, the range of companies benefiting from investor interest has not been limited to those developing a vaccine.

Vaccines 122

Vaccines Drug Pricing Compounding Immunity 122

pharmaphorum

NOVEMBER 23, 2021

Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs. billion earlier this year. Specific financial terms have not been disclosed.

Vaccines 105

Vaccines Immunity Immunization Drug Development 105

PharmaTech

JUNE 12, 2025

While BioNTech is best known for co-developing the first approved mRNA vaccine with Pfizer, the company continues to invest heavily in mRNA research targeting various solid tumors and infectious diseases. billion (1). billion (1). Implications of RFK Jr.’s

Dosage 52

Dosage Drug Development Vaccines Packaging 52

Pharmaceutical Technology

FEBRUARY 14, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 40

Diabetes Immunity Immunization Drug Development 40

Pharmaceutical Technology

JUNE 8, 2023

These solutions will help drug developers address the challenges of regulatory compliance, production scalability, quality assurance and cost-effectiveness. The new CGTs treat a broad range of indications including rare diseases, immune disorders and blood cancers.

Drug Development 52

Drug Development Vaccines Immunity Immunization 52

PharmaTech

JUNE 10, 2025

Digital art | Image Credit: © artacet - stock.adobe.com The biopharmaceutical industry has seen exciting advancements in the past decade, with cell and gene therapies, personalized medicine, messenger RNA (mRNA) vaccines, and new treatments for autoimmune diseases. Crucially, these modalities won’t exist in isolation.

Dosage 52

Dosage Drug Development Vaccines Compounding 52

PharmaShots

FEBRUARY 8, 2023

Moreover, the risks involved in drug development plans get minimalized by opening the doors to new opportunities and commercialization When it comes to life science collaborations, companies seek beyond the traditional interests of the partnership. Arcturus will also receive 40% of the profit from the COVID-19 vaccine sales.

Vaccines 56

Vaccines Drug Development Immunity Immunization 56